Drug intelligence / Profile preview

IgG-DM1

Development stage: Preclinical
Lead developer: Boston Children's Hospital
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IgG-DM1 is a non-targeting antibody-drug conjugate (ADC) designed as a control for targeted ADC studies. It comprises a non-targeting immunoglobulin G (IgG) antibody chemically linked to the potent cytotoxic agent Mertansine (DM1) via a non-cleavable succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) linker. In preclinical pancreatic cancer research, IgG-DM1 is utilized to differentiate the effects of the cytotoxic payload from the specific tumor-targeting capabilities of experimental ADCs like ICAM1-DM1, demonstrating the baseline cytotoxicity of DM1 in the absence of targeted delivery.

Other names: IgG-SMCC-DM1IgG-SMCC-DM-1IgG-SMCC-DM 1

Targets

Microtubule

Beyond the preview

Go deeper on IgG-DM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgG-DM1.

Explore the full profile